It is very uncertain whether summary of findings: Comparison 2 ‐ deferasirox (DFX) changes SAEs Thalassaemia‐related SAEs compared with deferiprone (DFO) (very low certainty).

1 finding from 1 review

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
RR 0.95 [0.41, 2.17]
2 studies · 247 participants
Very low

Deferasirox vs deferiprone (DFO)

SAEs ‐ SCD‐related SAEs

1 finding from 1 review

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 195 participants
Very low

Deferasirox vs deferiprone (DFO)

All‐cause mortality

1 finding from 1 review

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
0.96 [0.06, 15.42]
2 studies · 240 participants
Very low

Dose‐escalated RT vs conventional dose RT

Time to death from prostate cancerMedian · clinically localized and locally advanced prostate cancer

Dose‐escalated RT showed no clear difference in time to death from prostate cancer compared with conventional dose RT (moderate certainty).

1 finding from 1 review

Dose‐escalated radiotherapy for clinically localized and locally advanced prostate cancer 2023 · Cochrane Headline outcomes only
HR 0.83 [0.66, 1.04]
8 studies · 5231 participants
Moderate

Dose‐escalated RT vs conventional dose RT

Severe RT toxicity (grade ≥ 3) · clinically localized and locally advanced prostate cancer

Dose‐escalated RT probably leads to higher severe RT toxicity (grade ≥ 3) compared with conventional dose RT (moderate certainty).

1 finding from 1 review

Dose‐escalated radiotherapy for clinically localized and locally advanced prostate cancer 2023 · Cochrane Headline outcomes only
RR 1.72 [1.32, 2.25]
8 studies · 4992 participants
Moderate

Dose‐escalated RT vs conventional dose RT

Time to death from any cause · clinically localized and locally advanced prostate cancer

Dose‐escalated RT showed no clear difference in time to death from any cause compared with conventional dose RT (moderate certainty).

1 finding from 1 review

Dose‐escalated radiotherapy for clinically localized and locally advanced prostate cancer 2023 · Cochrane Headline outcomes only
HR 0.98 [0.89, 1.09]
9 studies · 5437 participants
Moderate

Dose‐escalated RT vs conventional dose RT

Time to distant metastasis · clinically localized and locally advanced prostate cancer

Dose‐escalated RT showed no clear difference in time to distant metastasis compared with conventional dose RT (moderate certainty).

1 finding from 1 review

Dose‐escalated radiotherapy for clinically localized and locally advanced prostate cancer 2023 · Cochrane Headline outcomes only
HR 0.83 [0.57, 1.22]
7 studies · 3499 participants
Moderate

Dose‐escalated RT vs conventional dose RT

Overall RT toxicity (grade ≥ 1) · clinically localized and locally advanced prostate cancer

Dose‐escalated RT may leads to higher overall RT toxicity (grade ≥ 1) compared with conventional dose RT (low certainty).

1 finding from 1 review

Dose‐escalated radiotherapy for clinically localized and locally advanced prostate cancer 2023 · Cochrane Headline outcomes only
RR 1.27 [1.04, 1.55]
7 studies · 4328 participants
Low

Dose‐escalated RT vs conventional dose RT

Quality of life · clinically localized and locally advanced prostate cancer

1 finding from 1 review

Dose‐escalated radiotherapy for clinically localized and locally advanced prostate cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 300 participants
Moderate

Alglucosidase alfa vs placebo

Change from baseline in 6MWT (metres) · 90 people with LOPD

1 finding from 1 review

Enzyme replacement therapy for late‐onset Pompe disease 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 90 participants
Moderate

Alglucosidase alfa plus clenbuterol vs alglucosidase alfa plus placebo

Infusion reactions · 13 people with LOPD

The review found no eligible studies for this question.

1 finding from 1 review

Enzyme replacement therapy for late‐onset Pompe disease 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Alglucosidase alfa plus clenbuterol vs alglucosidase alfa plus placebo

Need for respiratory support · 13 people with LOPD

The review found no eligible studies for this question.

1 finding from 1 review

Enzyme replacement therapy for late‐onset Pompe disease 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found